Vitara Biomedical, a Philadelphia, PA-based company developing technology intended to transform neonatal care, raised $50M in additional funding.
The round was led by Sands Capital with participation from Google Ventures (GV), First Spark Ventures, Flerie and Khosla Ventures.
The company intends to use the funds to further advance its efforts leading to a first in human clinical study of their technology.
Vitara Biomedical is developing a special life support system designed to improve outcomes for babies born prematurely. The Vitara System creates a fluid environment that mimics what a baby experiences in the mother’s womb and is designed to help support healthy growth and development of organs for babies born prematurely.
The company, which is pursuing a first in human clinical study of the Vitara System, also announced the appointment of Kim Rodriguez, an experienced global healthcare and medical device industry professional, as Chief Executive Officer.
Ms. Rodriguez is an experienced global healthcare and medical device industry professional. She has 25 years of experience, spanning multiple therapeutic areas, including neurology, cardiology, and women’s health, most recently as CEO of BrainCheck, a digital health company supporting early identification of dementia and Alzheimer’s disease. Prior to BrainCheck, Ms. Rodriguez was a Venture Partner at S3 Ventures, where she supported the firm’s healthcare investments. Previously she served as CEO & Co-Founder of Acessa Health (acquired By Hologic), CEO at Halt Medical, led the largest business unit at Spectranetics (acquired by Royal Philips) and Johnson & Johnson. She also held senior leadership positions Blockade Medical, Concentric Medical, Guidant Corporation, and Microvena/ev3 prior to each company’s acquisition by major medical device companies. Ms. Rodriguez received her Executive MBA from the University of Southern California Marshall School of Business and bachelor’s degree in management from Pepperdine University.
FinSMEs
19/11/2024